NMRA – neumora therapeutics, inc. (US:NASDAQ)

News

Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Neumora Therapeutics (NASDAQ:NMRA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $8.00 price target on the stock.
Neumora Therapeutics (NASDAQ:NMRA) was given a new $6.00 price target on by analysts at Mizuho.
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones [Yahoo! Finance]
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com